At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 105 enrolled
Drug / intervention
Levonorgestrel 52 mg intrauterine systemcombination
Likely dose
Levonorgestrel 52 mg intrauterine systemfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Multicenter, Open-Label Study of a Levonorgestrel 52 mg Intrauterine System for the Treatment of Heavy Menstrual Bleeding
In Brief
A Phase 3 clinical trial evaluating Levonorgestrel 52 mg intrauterine system for Menorrhagia. Completed, enrolled 105 participants across 29 sites.
Detailed Summary
To assess the efficacy of a levonorgestrel 52 mg intrauterine system as a treatment for heavy menstrual bleeding.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMenorrhagia
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
20192020202120222023202420252026
First PostedAug 2018
Enrollment StartJan 2019
Primary CompletionOct 2021
TodayJul 2026
First PostedAug 22, 2018
Enrollment StartJan 17, 2019
Primary CompletionOct 12, 2021
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 7.9 years ago
Interventions
Levonorgestrel 52 mg intrauterine systemcombination
Levonorgestrel 52 mg intrauterine system